JP6883988B2 - ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 - Google Patents

ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 Download PDF

Info

Publication number
JP6883988B2
JP6883988B2 JP2016541280A JP2016541280A JP6883988B2 JP 6883988 B2 JP6883988 B2 JP 6883988B2 JP 2016541280 A JP2016541280 A JP 2016541280A JP 2016541280 A JP2016541280 A JP 2016541280A JP 6883988 B2 JP6883988 B2 JP 6883988B2
Authority
JP
Japan
Prior art keywords
alkyl
aliphatic
isomer
aryl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016541280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500334A (ja
JP2017500334A5 (cg-RX-API-DMAC7.html
Inventor
ブリュー メコネン，
ブリュー メコネン，
ジョン エー． ブテーラ，
ジョン エー． ブテーラ，
ジアンシン フアン，
ジアンシン フアン，
Original Assignee
エージンバイオ， インコーポレイテッド
エージンバイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53403769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6883988(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エージンバイオ， インコーポレイテッド, エージンバイオ， インコーポレイテッド filed Critical エージンバイオ， インコーポレイテッド
Publication of JP2017500334A publication Critical patent/JP2017500334A/ja
Publication of JP2017500334A5 publication Critical patent/JP2017500334A5/ja
Application granted granted Critical
Publication of JP6883988B2 publication Critical patent/JP6883988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2016541280A 2013-12-20 2014-12-19 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 Active JP6883988B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361919390P 2013-12-20 2013-12-20
US201361919394P 2013-12-20 2013-12-20
US61/919,390 2013-12-20
US61/919,394 2013-12-20
US201462075743P 2014-11-05 2014-11-05
US62/075,743 2014-11-05
PCT/US2014/071644 WO2015095783A1 (en) 2013-12-20 2014-12-19 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2019193538A Division JP2020011998A (ja) 2013-12-20 2019-10-24 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Division JP2021080287A (ja) 2013-12-20 2021-03-01 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Publications (3)

Publication Number Publication Date
JP2017500334A JP2017500334A (ja) 2017-01-05
JP2017500334A5 JP2017500334A5 (cg-RX-API-DMAC7.html) 2018-02-01
JP6883988B2 true JP6883988B2 (ja) 2021-06-09

Family

ID=53403769

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016541280A Active JP6883988B2 (ja) 2013-12-20 2014-12-19 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2019193538A Pending JP2020011998A (ja) 2013-12-20 2019-10-24 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Withdrawn JP2021080287A (ja) 2013-12-20 2021-03-01 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019193538A Pending JP2020011998A (ja) 2013-12-20 2019-10-24 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Withdrawn JP2021080287A (ja) 2013-12-20 2021-03-01 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Country Status (11)

Country Link
US (2) US10329301B2 (cg-RX-API-DMAC7.html)
EP (2) EP4032889A1 (cg-RX-API-DMAC7.html)
JP (3) JP6883988B2 (cg-RX-API-DMAC7.html)
CN (2) CN106068256B (cg-RX-API-DMAC7.html)
AU (1) AU2014368961B2 (cg-RX-API-DMAC7.html)
CA (2) CA2934553C (cg-RX-API-DMAC7.html)
IL (1) IL246261B (cg-RX-API-DMAC7.html)
MX (2) MX381561B (cg-RX-API-DMAC7.html)
NZ (2) NZ722077A (cg-RX-API-DMAC7.html)
WO (1) WO2015095783A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201605027B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2818025A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
EP4032889A1 (en) 2013-12-20 2022-07-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA2990004C (en) * 2015-06-19 2024-04-23 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10449181B2 (en) 2016-08-25 2019-10-22 Sarah E. Labance Treatment of autism and autism spectrum disorders (ASD)
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio, Inc. derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
AU2019288382B2 (en) * 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2020165802A1 (en) * 2019-02-13 2020-08-20 Centre For Addiction And Mental Health Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
US12187737B2 (en) 2019-06-04 2025-01-07 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
MX2022007725A (es) * 2019-12-19 2022-07-19 Agenebio Inc Derivados de benzodiazepinas, composiciones y metodos para tratar deterioro cognitivo.
AU2021244926A1 (en) 2020-03-26 2022-11-03 Richter Gedeon Nyrt. Naphthyridine and pyrido(3,4-c)pyridazine derivatives as GABAA a5 receptor modulators
IL299761A (en) * 2020-07-10 2023-03-01 Agenebio Inc GABAA alpha 5 agonist polymorphs and methods of use for the treatment of cognitive impairment
US20230270753A1 (en) * 2020-07-10 2023-08-31 Agenebio, Inc. Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment
CN113284553B (zh) * 2021-05-28 2023-01-10 南昌大学 一种用于治疗药物成瘾的药物靶点结合能力测试方法
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
AU2023324882A1 (en) 2022-08-19 2025-03-20 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
US20250375429A1 (en) 2024-05-29 2025-12-11 Smarter Not Harder, Inc. Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
NL7305644A (cg-RX-API-DMAC7.html) 1972-04-20 1973-10-23
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
EP0402644B1 (en) 1989-05-19 1995-08-16 Hoechst-Roussel Pharmaceuticals Incorporated N-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines,a process for their preparation and their use as medicaments
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
ATE180475T1 (de) * 1990-09-21 1999-06-15 Rohm & Haas Dihydropyridazinone und pyridazinone als fungizide
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5500438A (en) * 1991-05-24 1996-03-19 E. I. Du Pont De Nemours And Company Arthropodicidal anilides
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
TW201311B (cg-RX-API-DMAC7.html) * 1991-06-17 1993-03-01 Hoffmann La Roche
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
CA2182981C (en) 1994-03-02 2006-10-17 Leonardus Petrus Carla Delbressine Sublingual or buccal pharmaceutical composition
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
AU1041599A (en) 1997-11-13 1999-06-07 Jose Luis Castro Pineiro Therapeutic uses of triazolo-pyridazine derivatives
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
EP1129094A2 (en) 1998-11-12 2001-09-05 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
EP1157989B1 (en) 1999-03-03 2004-09-22 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
GB9911802D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911803D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911804D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9929569D0 (en) 1999-12-14 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
CZ20032338A3 (cs) 2001-03-01 2004-08-18 Pfizeráproductsáinc Použití inversních agonistů GABA A v kombinaci s parciálními agonisty receptoru nikotinuŹ estrogenemŹ selektivními modulátory estrogenu nebo vitaminem E při léčení kognitivních poruch
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
US20050071088A1 (en) 2001-08-13 2005-03-31 Landfield Philip W Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
JP2005518411A (ja) 2002-01-16 2005-06-23 エンド ファーマシューティカルズ インコーポレーテッド 中枢神経系の障害を治療する製薬組成物及び方法
CA2495285A1 (en) 2002-08-13 2004-02-19 Merck Sharp & Dohme Limited Phenylpyridazine derivatives as ligands for gaba receptors
GB0218876D0 (en) 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
WO2004037234A2 (en) 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US20040191803A1 (en) 2002-11-22 2004-09-30 Michela Gallagher Target for therapy of cognitive impairment
TW200526194A (en) 2003-10-22 2005-08-16 Merz Pharma Gmbh & Co Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic Aβ peptides in amyloidopathies
CN101374525A (zh) 2004-09-23 2009-02-25 莫茨药物股份两合公司 美金刚治疗儿童行为障碍
AU2005293820B2 (en) 2004-10-12 2010-11-25 F. Hoffmann-La Roche Ag Imidazo [1, 5-a]triazolo[1, 5-d]benzodiazepine derivatives for the treatment of cognitive disorders
CA2584259C (en) * 2004-10-20 2013-04-02 F. Hoffmann-La Roche Ag Imidazo-benzodiazepine derivatives
RU2007114763A (ru) 2004-10-20 2008-11-27 Ф.Хоффманн-Ля Рош Аг (Ch) Галогенозамещенные производные бензодиазепинов
EP1828194B1 (en) * 2004-12-14 2008-05-28 F. Hoffmann-Roche AG Tetracyclic imidazo-benzodiazepines as gaba receptors modulators
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
CA2607226A1 (en) 2005-05-16 2007-02-15 Wisys Technology Foundation, Inc. Gabaergic agents to treat memory deficits
EP1924712B1 (en) 2005-08-03 2018-10-03 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
BRPI0617204A2 (pt) 2005-10-11 2011-07-19 Hoffmann La Roche derivados de imidazo benzodiazepina
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
EP2330891A1 (en) 2008-09-24 2011-06-15 E. I. du Pont de Nemours and Company Fungicidal pyridazines
CA2737452C (en) 2008-09-25 2018-05-22 Vive Nano Inc. Methods to produce polymer nanoparticles and formulations of active ingredients
WO2010120370A2 (en) 2009-04-17 2010-10-21 Xenoport, Inc. Gamma-amino-butyric acid derivatives as gabab receptor ligands
WO2011085406A1 (en) 2010-01-11 2011-07-14 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
PH12013500676A1 (en) * 2010-11-05 2013-05-06 Hoffmann La Roche Use of active pharmaceutical compounds for the treatment of central nervous system conditions
US20130237530A1 (en) 2010-11-15 2013-09-12 Agenebio, Inc. Benzodiazepine derivatives, compositions and methods for treating cognitive impairment
CA2818025A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012161133A1 (ja) 2011-05-20 2012-11-29 日産化学工業株式会社 置換ピリダジン化合物及び農園芸用殺菌剤
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
US20150224094A1 (en) 2012-09-10 2015-08-13 Ophirex, Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
EP4032889A1 (en) 2013-12-20 2022-07-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA2990004C (en) 2015-06-19 2024-04-23 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN108567787A (zh) 2017-03-10 2018-09-25 辛衍雪 一种治疗慢性阻塞性肺病的药物组合物
AU2019288382B2 (en) 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Also Published As

Publication number Publication date
IL246261A0 (en) 2016-08-02
IL246261B (en) 2021-03-25
AU2014368961A1 (en) 2016-08-04
NZ760341A (en) 2021-12-24
US20190284196A1 (en) 2019-09-19
EP3083569A1 (en) 2016-10-26
MX2016007808A (es) 2016-09-07
CA3123897A1 (en) 2015-06-25
CN112409363A (zh) 2021-02-26
EP3083569B1 (en) 2022-01-26
MX381561B (es) 2025-03-12
US20170022208A1 (en) 2017-01-26
CA3123897C (en) 2024-02-06
CN106068256B (zh) 2020-10-23
WO2015095783A1 (en) 2015-06-25
NZ722077A (en) 2021-12-24
US11142529B2 (en) 2021-10-12
CN106068256A8 (zh) 2018-10-30
CN112409363B (zh) 2023-11-14
MX2019010577A (es) 2019-10-21
MX391314B (es) 2025-03-21
JP2020011998A (ja) 2020-01-23
CA2934553C (en) 2023-10-31
ZA201605027B (en) 2023-04-26
JP2017500334A (ja) 2017-01-05
AU2014368961A2 (en) 2016-11-10
CN106068256A (zh) 2016-11-02
US10329301B2 (en) 2019-06-25
AU2014368961B2 (en) 2019-10-17
US20170253603A2 (en) 2017-09-07
BR112016014564A2 (pt) 2017-08-08
JP2021080287A (ja) 2021-05-27
CA2934553A1 (en) 2015-06-25
EP3083569A4 (en) 2017-10-04
EP4032889A1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
JP6883988B2 (ja) ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US12024525B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20230134844A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20200048268A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN115175911A (zh) 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法
US11505555B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40077472A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016046A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40016046B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254300A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254300B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230170B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230170A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EA039381B1 (ru) Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171218

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191024

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191024

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191111

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20191112

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191220

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20191224

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200630

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200831

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210322

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210415

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210511

R150 Certificate of patent or registration of utility model

Ref document number: 6883988

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250